0.12 (0.36%) 1d

Related posts

Markets rise, but mixed
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Biohaven Pharmaceutical (BHVN-N) has been experiencing ups and downs in the stock market. The FDA's refusal to review one of their drugs led to a sell-off, but some experts see this as a potential buying opportunity. The company is currently not profitable, but there is optimism surrounding their new drugs in the pipeline. Biohaven's recent R&D day resulted in a significant increase in share price, signaling investor faith in their future prospects.


Shares sold off last week after the FDA refused to review one of their drugs. Could be a buying opportunity, but the company is losing money.

Pharma & Healthcare

The new Biohaven began trading last October after Pfizer bought the old one only for its migraine drug. The new Biohaven is far more speculative because there are many drugs in the pipeline in early stages. They held an R&D day this week and shares soared. He has faith in their new drugs.

Pharma & Healthcare
A favourite of his. It plunged from $139 to $121 today. Whoa. Yesterday morning, they reported a solid quarter, and partnered with Pfizer to sell their big migraine pill overseas. But BHVN pre-announced strong results in early October so the good news is baked into the stock. The Pfizer news may be seen as a negative, because many investors expected BHVN to be a takeover candidate.
Pharma & Healthcare
The caller bought at $33 It reports tomorrow afternoon. He likes it alot and uses their migraine money. Sell an amount equal to your cost based on $33/shares, then let it run. This way, you can't lose money.
Pharma & Healthcare
Their super pill helped him control his migraine, so he's a fan of this stock.
Pharma & Healthcare
Their drugs treated his migraine beautifully. The stock was downgraded yesterday, but he loves it.
Pharma & Healthcare
They sell a super migraine pill he uses. It popped a year from around $25 to $100 in November, but since then it's pulled back to $72 today. It's a victim of the current rotation out of tech into cyclicals. That migraine pill is a steady seller and Biohaven also has a Parkinson's treatment in the pipeline as well as one for ALS. It could be worth buying into weakness.
Pharma & Healthcare
Renown for their new migraine drug. Shares have tripled since April. He see more upside with their migraine pill (which he himself has taken and it's effective). Also consider their Alzheimer's drug which is being tested now.
Pharma & Healthcare
Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

Biohaven Pharmaceutical (BHVN-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Biohaven Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Biohaven Pharmaceutical (BHVN-N) Frequently Asked Questions

What is Biohaven Pharmaceutical stock symbol?

Biohaven Pharmaceutical is a American stock, trading under the symbol BHVN-N on the New York Stock Exchange (BHVN). It is usually referred to as NYSE:BHVN or BHVN-N

Is Biohaven Pharmaceutical a buy or a sell?

In the last year, 2 stock analysts published opinions about BHVN-N. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Biohaven Pharmaceutical .

Is Biohaven Pharmaceutical a good investment or a top pick?

Biohaven Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Biohaven Pharmaceutical .

Why is Biohaven Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Biohaven Pharmaceutical worth watching?

2 stock analysts on Stockchase covered Biohaven Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Biohaven Pharmaceutical stock price?

On 2024-06-21, Biohaven Pharmaceutical (BHVN-N) stock closed at a price of $33.56.